Clinical trial · Observational
REBECCA Real-world Early BrEast CanCer mAnagement
REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
NCT06856343CI-TRIAL-00123715REBECCArecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Proportion of patients who receive Olaparib for the full treatment duration
- timeFrame
- 18 months after inclusion
- description
- The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.
Secondary outcomes (4)
- measure
- BRCA characteristics: Mutation type
- timeFrame
- 18 months after inclusion
- description
- Regarding BRCA characteristics: Mutation type: Tumoral (if only tumoral testing performed), somatic, germline.
- measure
- Type of variants
- timeFrame
- 18 months after inclusion
- description
- Type of variants: BRCA1 and/or BRCA2, PALB2 mutation, presence of other HRR gene mutations, presence of other mutations
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study. Exclusion Criteria: * Patient not consenting to participate. * Patients included in the Early Access Program
References
Publications (0)
Data not yet available
No reference posted for this study.